Rishi N. Reddy
Co-Founder & Executive Chairman @ ChronicleBio
Newport Beach, United States
Rishi N. Reddy is a seed investor at ChronicleBio in Newport Beach focused on Health Care and Travel. Rishi N. Reddy is based out of Newport Beach, California and is the Co-Founder and Executive Chairman of ChronicleBio. Rishi previously worked at Cue Health Inc. as a Board Observer. Rishi N. Reddy attended Wharton School of the University of Pennsylvania.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Rishi N. Reddy invests in
Stages Rishi N. Reddy invests in
Countries Rishi N. Reddy invests in
Investment Focus
Industry
- Health Care 2 (50%)
- Travel 1 (25%)
- FinTech 1 (25%)
- Tourism 1 (25%)
- Training 1 (25%)
Stage
- Seed 1 (25%)
- Series A 1 (25%)
- Series B 1 (25%)
- Series D 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Chronus Health
|
Chronus Health is a portable platform that enables doctors to provide real-time treatment based on actual lab results. The company developing a portable CLIA waived system to deliver point-of-care lab results in minutes. It allows for real-time diagnosis at the point-of-care providing lab results in minutes, dramatically improving patient outcomes.Chronus Health was founded in 2017 and is headquartered in Mountain View, California, United States. | $22M / Series A / Jan 12, 2022 | |
Petal
|
Petal is a credit card company that is built to help people financially succeed. It aims to make credit honest, simple, and accessible. The company uses machine learning to analyze a customer’s full digital financial record—not just their credit score.Petal has pioneered cash flow underwriting, as an alternative to credit scores, to make creditmore accessible, and offers a simple, modern digital experience that encourages members to build credit, avoid debt, and spend responsibly. Petal is based in New York, New York, and Richmond, Virginia. The Petal credit card is issued by WebBank, Member FDIC. | $140M / Series D / Jan 05, 2022 | |
AvantStay
|
AvantStay is the premier next generation hospitality platform. We are redefining the way in which people travel, transact and invest. AvantStay assures a highly-curated experience customized to guests’ needs, using a proprietary tech suite to power bookings, seamlessly operationalize in-field and remote management, and activate authentic andelevated consumer touch points. AvantStay currently operates in over 60 cities, with a drive-to market approach, including 450+ premier properties across their diversified portfolio, and an AUM of more than $800M. In 2019, AvantStay became one of the initial twelve partners of Homes & Villas by Marriott International, and currently offers direct bookings on more than 50 OTAs. | $160M / Series B / Dec 15, 2021 | |
ClinTrial Research
|
ClinTrial Research is a clinical trial services firm that provides site management, patient recruitment, and regulatory support services. | Seed |
Co-Investors
About ChronicleBio
ChronicleBio Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Rishi N. Reddy
Co-Founder & Executive Chairman
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Rishi N. Reddy invest in?
Rishi N. Reddy invests primarily in Health Care, Travel and FinTech startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Rishi N. Reddy last invest?
The most recent investment recorded for Rishi N. Reddy closed in Jan 2022. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
